Literature DB >> 22808729

[Occurrence of alert pathogens in hospital environment Part II. Multidrug-resistant non-fermenting bacilli].

Paulina Paluchowska1, Małgorzata Skałkowska, Anna Spelak, Alicja Budak.   

Abstract

INTRODUCTION: Multidrug-resistant gram-negative non-fermenting bacilli are an important cause of nosocomial infection. Aim of this study was to analyze the prevalence and antimicrobial susceptibility of rods of the species Acinetobacter baumannii and Pseudomonas aeruginosa, belonging to multidrug-resistant alert pathogens.
METHODS: 105 (70%) strains of A. baumannii and 46 (30%) strains of P. aeruginosa were isolated from 125 patients hospitalized in the Specialistic Hospital in Krakow, in the years 2008-2010. Taken into account first isolate from the patient. The condition for inclusion in the study was the resistance or reduced susceptibility to selected groups of antibiotics, such as beta-lactams, aminoglycosides and fluoroquinolones. Bacterial identification and antimicrobial susceptibility testing were performed by automated system Vitek 2 Compact (bioMerieux, Poland). All strains were tested with phenotypic method Etest MBL (AB Biodisk, Sweden) for the presence of resistance mechanism associated with the production of metallo-beta-lactamases.
RESULTS: Bacilli of the species A. baumannii were isolated most frequently from patients from the Department of Anesthesiology and Intensive Care (52%) and Burn Therapy Unit (25%), with clinical materials collected from the respiratory tract (51%), the wound swabs (18%), urine (11%) and blood (11%). Production of metallo-beta-lactamases was found in 24 (22.9%) strains of A. baumannii. Drugs effective against multidrug-resistant isolates of A. baumannii were colistin and amikacin. Department of anesthesiology and intensive care (59%) and unit of internal medicine (11%) were the main source of multidrug-resistant strains of P. aeruginosa. Pathogens were mainly isolated from clinical specimens collected from the respiratory tract (61%), urine (15%) and wound swabs (13%). Seven (15.2%) strains of P. aeruginosa produced the metallo-beta-lactamases. With regard to colistin and piperacillin with tazobactam was noted the highest percentage of susceptible isolates.
CONCLUSIONS: MDR bacteria belonging to alert pathogens are an important cause of many severe and difficult to treat infections which greatly increases the morbidity and mortality among hospitalized patients worldwide. Epidemiological studies and detection of local resistance patterns can provide useful information which can be used in the development of strategies to combat the rising tide of microbial antibiotic resistance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22808729

Source DB:  PubMed          Journal:  Med Dosw Mikrobiol        ISSN: 0025-8601


  3 in total

1.  Molecular Detection of Drug-Resistance Genes of blaOXA-23-blaOXA-51 and mcr-1 in Clinical Isolates of Pseudomonas aeruginosa.

Authors:  Fabiana Nitz; Bruna Oliveira de Melo; Luís Cláudio Nascimento da Silva; Andrea de Souza Monteiro; Sirlei Garcia Marques; Valério Monteiro-Neto; Rosimary de Jesus Gomes Turri; Antonio Dantas Silva Junior; Patrícia Cristina Ribeiro Conceição; Hilário José Cardoso Magalhães; Adrielle Zagmignan; Thiago Azevedo Feitosa Ferro; Maria Rosa Quaresma Bomfim
Journal:  Microorganisms       Date:  2021-04-09

2.  Alert Germ Infections: Chest X-ray and CT Findings in Hospitalized Patients Affected by Multidrug-Resistant Acinetobacter baumannii Pneumonia.

Authors:  Raffaella Capasso; Antonio Pinto; Nicola Serra; Umberto Atripaldi; Adele Corcione; Giorgio Bocchini; Salvatore Guarino; Roberta Lieto; Gaetano Rea; Giacomo Sica; Tullio Valente
Journal:  Tomography       Date:  2022-06-14

3.  Prevalence of resistance to aminoglycosides and fluoroquinolones among Pseudomonas aeruginosa strains in a University Hospital in Northeastern Poland.

Authors:  Anna Diana Michalska; Pawel Tomasz Sacha; Dominika Ojdana; Anna Wieczorek; Elzbieta Tryniszewska
Journal:  Braz J Microbiol       Date:  2015-03-04       Impact factor: 2.476

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.